If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Some fission products decay with the release of delayed neutrons, important to nuclear reactor control. Other fission products, such as xenon-135 and samarium-149, have a high neutron absorption cross section. Since a nuclear reactor must balance neutron production and absorption rates, fission products that absorb neutrons tend to "poison" or shut the reactor down; this is controlled with burnable poisons and control rods. Build-up of xenon-135 during shutdown or low-power operation may poison the reactor enough to impede restart or interfere with normal control of the reaction during restart or restoration of full power. This played a major role in the Chernobyl disaster.
== Early years and education == Hans Charles Freeman was the first and only son of Karl and Lotte Freeman and was born in Breslau in Germany in 1929 (now Wrocław, Poland). In 1938, following a tip-off from a Nazi party member, Karl decided to relocate his Jewish family to Australia. Karl brought his knowledge of detergents (a novelty in Australia at the time) to his new homeland, applying it to the problem of cleaning blood-stained blankets that would otherwise be wasted. After the war, he founded K. H. Freeman Pty Ltd, a detergent and soap manufacturing company; Hans spent many weekends working in the factory, gaining a practical insight into chemistry. Hans adapted well to his new environment, quickly mastering his new language and demonstrating his outstanding scholastic ability. He was dux of his primary school, dux of Sydney Boys High in 1945, and took his bachelor's degree with the university medal in chemistry in 1949. He was one of the ten chemistry students in his class at Sydney Boys High to go on to become Professors of Chemistry. After receiving his MSc in 1952 under the supervision of Raymond Le Fèvre FRS, Freeman attended Caltech on a Rotary Foundation Fellowship where, at the urging of Linus Pauling, he learned the fundamentals of crystallography. He received a PhD in 1957 for his work on the structure of biuret hydrate, where he completed most of the calculations for the crystal structure by hand.
BK's early success in the field was overshadowed by a 1982 deal between McDonald's and The Walt Disney Company to promote Disney's animated films beginning in the mid-1980s and running through the early 1990s. In 1994, Disney switched from McDonald's to Burger King, signing a 10-movie promotional contract which would include such top 10 films as Disney Animation's Aladdin (1992), Beauty and the Beast (1991), The Lion King (1994), and Pixar's Toy Story (1995). Burger King created kids' meal toys to promote the DreamWorks Pictures film Small Soldiers (1998). This led to some controversy due to the film being rated PG-13. As a result, BK altered the promotional commercials to be directed at an older audience, and included a pamphlet disclaimer with the toys which read, in part; "the movie Small Soldiers may contain material that is inappropriate for younger children." A partnership in association with the Pokémon franchise at the height of its popularity in 1999 was tremendously successful for the company, with many locations rapidly selling out of the toys and the replacements. In December 1999, two hazardous incidents involving the Pokéball toy, one of which caused the death of a 13-month-old child, led to the toy being recalled. Shortly after the acquisition of Burger King by TPG Capital, L.P. in 2002, its new CEO Brad Blum set about turning around the fortunes of the company by initiating an overhaul of its flailing advertising programs.
==== Cancer health claims ==== The U.S. Food and Drug Administration initiated a process of reviewing and approving food and dietary supplement health claims in 1993. Reviews of petitions results in proposed claims being rejected or approved. If approved, specific wording is allowed on package labels. In 1999, a second process for claims review was created. If there is not a scientific consensus on the totality of the evidence, a Qualified Health Claim (QHC) may be established. The FDA does not "approve" qualified health claim petitions. Instead, it issues a Letter of Enforcement Discretion that includes very specific claim language and the restrictions on using that wording. The first QHCs relevant to vitamin E were issued in 2003: "Some scientific evidence suggests that consumption of antioxidant vitamins may reduce the risk of certain forms of cancer." In 2009, the claims became more specific, allowing that vitamin E might reduce the risk of renal, bladder and colorectal cancers, but with required mention that the evidence was deemed weak and the claimed benefits highly unlikely. A petition to add brain, cervical, gastric and lung cancers was rejected. A further revision, May 2012, allowed that vitamin E may reduce risk of renal, bladder and colorectal cancers, with a more concise qualifier sentence added: "FDA has concluded that there is very little scientific evidence for this claim." Any company product label making the cancer claims has to include a qualifier sentence.
For services to Life Saving. Geoffrey Francis Norris, General Medical Practitioner, London. For services to Medicine. Arthur Joseph Nutter. For services to the Lieutenancy in Lancashire. John O'Neil, lately Principal Lecturer and Course Leader of PGCE Art and Design, University of Wales Institute, Cardiff. For services to Art Education and Teacher Training. Martin Offiah. For services to Rugby Football. Enid Rosalind Oliver. For services to the community in Ashford, Kent. William James Orford. For services to Cricket in the West Midlands. Vera Overs. For services to the community in Martindale, Cumbria. Clifford Owen. For services to the Chorley and District Talking Newspaper, Lancashire. Pamela Mary Owen. For services to the community, particularly the NHS, in Welshpool, Powys. Anthony Gerald Palmer. For services to the War Pensions Committee in East Anglia. Sarah Faith, The Honourable Mrs. Palmer. For services to the community, particularly the British Red Cross Society, in Berkshire. Isobel Marilyn Park. For services to the Scout Association in Dumfries. Gordon Seymour Passmore, Member, London Borough of Wandsworth. For services to Local Government. Norman Henry Pattenden, Special Operations Manager, North & South Railways Ltd. For services to the Railways Industry. William Evans Pattison. For services to Mountain Rescue. Robert John Patton. For services to the Engineering Industry. Christine Anne Pendlebury, Personal Secretary, Home Office. Philippa Helen Perks. For services to the community in Wrington, Bristol.
Sources: en.wikipedia.org
=== Causality === Early case-control studies clearly showed a close association between smoking and lung cancer, but contemporary doctors and scientists did not feel evidence existed for causality. Follow-up large prospective cohort studies in the early 1950s showed clearly that smokers died faster, and were more likely to die of lung cancer, cardiovascular disease, and a list of other diseases which lengthened as the studies continued The British Doctors Study, a longitudinal study of some 40,000 doctors, began in 1951. By 1954 it had evidence from three years of doctors' deaths, based on which the government issued advice that smoking and lung cancer rates were related (the British Doctors Study last reported in 2001, by which time there were approximately 40 linked diseases). The British Doctors Study demonstrated that about half of the persistent cigarette smokers born in 1900–1909 were eventually killed by their addiction.
=== Amino acid biosynthesis === All amino acids are formed from intermediates in the catabolic processes of glycolysis, the citric acid cycle, or the pentose phosphate pathway. From glycolysis, glucose 6-phosphate is a precursor for histidine; 3-phosphoglycerate is a precursor for glycine and cysteine; phosphoenol pyruvate, combined with the 3-phosphoglycerate-derivative erythrose 4-phosphate, forms tryptophan, phenylalanine, and tyrosine; and pyruvate is a precursor for alanine, valine, leucine, and isoleucine. From the citric acid cycle, α-ketoglutarate is converted into glutamate and subsequently glutamine, proline, and arginine; and oxaloacetate is converted into aspartate and subsequently asparagine, methionine, threonine, and lysine.
=== History of ideas === Brown, T.M. (1965). "Resource letter EEC-1 on the evolution of energy concepts from Galileo to Helmholtz". American Journal of Physics. 33 (10): 759–765. Bibcode:1965AmJPh..33..759B. doi:10.1119/1.1970980. Cardwell, D.S.L. (1971). From Watt to Clausius: The Rise of Thermodynamics in the Early Industrial Age. London: Heinemann. ISBN 978-0-435-54150-7. Guillen, M. (1999). Five Equations That Changed the World. New York: Abacus. ISBN 978-0-349-11064-6. Hiebert, E.N. (1981). Historical Roots of the Principle of Conservation of Energy. Madison, Wis.: Ayer Co Pub. ISBN 978-0-405-13880-5. Kuhn, T.S. (1957) "Energy conservation as an example of simultaneous discovery", in M. Clagett (ed.) Critical Problems in the History of Science pp.321–56 Sarton, G.; Joule, J. P.; Carnot, Sadi (1929). "The discovery of the law of conservation of energy". Isis. 13: 18–49. doi:10.1086/346430. S2CID 145585492. Smith, C. (1998). The Science of Energy: Cultural History of Energy Physics in Victorian Britain. London: Heinemann. ISBN 978-0-485-11431-7. Mach, E. (1872). History and Root of the Principles of the Conservation of Energy. Open Court Pub. Co., Illinois. Poincaré, H. (1905). Science and Hypothesis. Walter Scott Publishing Co. Ltd; Dover reprint, 1952. ISBN 978-0-486-60221-9. {{cite book}}: ISBN / Date incompatibility (help), Chapter 8, "Energy and Thermo-dynamics"
Calcineurin, in turn, activates NFAT, which then translocates to the nucleus. NFAT is a transcription factor that activates the transcription of a pleiotropic set of genes, most notable, IL-2, a cytokine that promotes long-term proliferation of activated T cells. PLC-γ can also initiate the NF-κB pathway. DAG activates PKC-θ, which then phosphorylates CARMA1, causing it to unfold and function as a scaffold. The cytosolic domains bind an adapter BCL10 via CARD (Caspase activation and recruitment domains) domains; that then binds TRAF6, which is ubiquitinated at K63. This form of ubiquitination does not lead to degradation of target proteins. Rather, it serves to recruit NEMO, IKKα and -β, and TAB1-2/ TAK1. TAK 1 phosphorylates IKK-β, which then phosphorylates IκB allowing for K48 ubiquitination: leads to proteasomal degradation. Rel A and p50 can then enter the nucleus and bind the NF-κB response element. This coupled with NFAT signaling allows for complete activation of the IL-2 gene. While in most cases activation is dependent on TCR recognition of antigen, alternative pathways for activation have been described. For example, cytotoxic T cells have been shown to become activated when targeted by other CD8 T cells leading to tolerization of the latter. In spring 2014, the T-Cell Activation in Space (TCAS) experiment was launched to the International Space Station on the SpaceX CRS-3 mission to study how "deficiencies in the human immune system are affected by a microgravity environment". T cell activation is modulated by reactive oxygen species.
Sources: en.wikipedia.org
British scientists also used unconventional methods for sourcing possible bomb debris: workers holidaying in Europe were instructed to collect pinecones, and crates of tea leaves were imported from China.
) is a pharmacokinetic parameter representing the efficiency of drug elimination. This is the rate of elimination of a substance divided by its concentration. The parameter also indicates the theoretical volume of plasma from which a substance would be completely removed per unit time. Usually, clearance is measured in L/h or mL/min. Excretion, on the other hand, is a measurement of the amount of a substance removed from the body per unit time (e.g., mg/min, μg/min, etc.). While clearance and excretion of a substance are related, they are not the same thing. The concept of clearance was described by Thomas Addis, a graduate of the University of Edinburgh Medical School. Substances in the body can be cleared by various organs, including the kidneys, liver, lungs, etc. Thus, total body clearance is equal to the sum clearance of the substance by each organ (e.g., renal clearance + hepatic clearance + pulmonary clearance = total body clearance). For many drugs, however, clearance is solely a function of renal excretion. In these cases, clearance is almost synonymous with renal clearance or renal plasma clearance. Each substance has a specific clearance that depends on how the substance is handled by the nephron. Clearance is a function of 1) glomerular filtration, 2) secretion from the peritubular capillaries to the nephron, and 3) reabsorption from the nephron back to the peritubular capillaries.
is found similarly. Substituting these nuclear masses into the Q-value equation, while neglecting the nearly zero antineutrino mass and the difference in electron binding energies, which is very small for high-Z atoms, we have
==== Mastocytosis ==== Mastocytosis involves both excessive accumulation and activation of mast cells and is considered a primary type of mast cell activation disorder (MCAD). Mastocytosis is a rare clonal mast cell disorder involving rapid, uncontrolled cell growth and the presence of too many mast cells (mastocytes). The most commonly affected organs in mastocytosis are bone marrow, skin, liver, spleen, and lymph nodes. Symptoms of mastocytosis depend upon the organs involved. In 2016, the World Health Organization (WHO) classified mastocytosis as cutaneous (CM, skin only), systemic (SM, involving at least one additional organ) or mast cell sarcoma (MCS, involving rapidly spreading solid tumors). In 2022, WHO divided SM into subcategories which include the less advanced forms of bone marrow mastocytosis (BMM), indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), and the more advanced forms of aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL). Although not always present, mutations in KIT appear to result in uncontrolled growth of MCs. The KITD816V mutation is present in over 90% of mastocytosis patients. It is located in exon 17 in the intracellular tyrosine kinase 2 (TK2) domain. This mutation, as well as expression of either CD2 or CD25 (confirmed by immunostaining or flow cytometry), are characteristic of primary clonal/monoclonal mast cell activation syndrome (CMCAS/MMAS).
=== Liver disease === The SAM cycle has been closely tied to the liver since 1947 because people with alcoholic cirrhosis of the liver would accumulate large amounts of methionine in their blood. While multiple lines of evidence from laboratory tests on cells and animal models suggest that SAM might be useful to treat various liver diseases, as of 2012 SAM had not been studied in any large randomized placebo-controlled clinical trials that would allow an assessment of its efficacy and safety.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.